Published online before print January 3, 2008, doi: 10.1161/ATVBAHA.107.159178
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2008 American Heart Association, Inc.
Translational Therapeutics at the Platelet Vascular Interface: A CME-Certified Activity |
Oxidative Stress and Platelets
From the Boston University School of Medicine, Mass.
Correspondence to Jane E. Freedman, Boston University School of Medicine, 715 Albany Street, W507, Boston, MA 02118. E-mail freedmaj{at}bu.edu
 |
Abstract |
|---|
Top
Abstract
IntroductionPlatelet-dependent thrombus formation may be influenced by alteration of platelet or vascular redox state, the presence of endogenous or exogenous antioxidants, as well as the formation of reactive oxygen and nitrogen species. Specifically, settings and pathways that influence the formation of superoxide and nitric oxide, as well as their metabolism, may influence platelet function and thrombus formation. Although some antioxidant regimens have been associated with bleeding and hemorrhagic stroke, the therapeutic value of antioxidants in clinical syndromes that lead to platelet-dependent thrombosis is not clear, as supplemental antioxidants have not been generally associated with better cardiovascular outcome.
Key Words: platelet • antioxidant • thrombosis • redox
|
Introduction |
|---|
This article is part of a multi-part CME-certified activity titled Translational Therapeutics at the Platelet Vascular Interface. In order to achieve all of the activity’s learning objectives, please read all of the components of the activity listed in the Table of Contents and follow the "Instructions for Participation and Obtaining CME Credit" outlined prior to the Introduction.
Redox changes occur as a function of normal platelet activation; however, the introduction of additional oxidative stress in certain settings may be prothrombotic. Modulation of platelet or vascular redox status, the presence of reactive oxygen species, and the addition of exogenous antioxidants can alter platelet activation in vitro and in vivo and may have (patho)physiological ramifications.
The clinical role of oxidative stress in platelet function and thrombosis is not straightforward. Although earlier epidemiological studies found that dietary antioxidant consumption was inversely associated with the development of coronary artery disease, more recent studies of vitamin supplementation have presented conflicting or negative results.1 Interestingly, some of the negative side effects of antioxidant therapies, such as enhanced hemorrhagic stroke, may be attributed to changes in the thrombotic response. Although the effects of antioxidants were attributed to the prevention of oxidative modification of low-density lipoprotein (LDL) and the inhibition of atherogenesis, other effects may be relevant, including regulation of platelet activation, which is dependent on the balance between oxidative stress and redox state. As platelet function has also been implicated in the development of atherosclerosis and in the acute occlusion of coronary vessels,2,3 oxidative processes and platelet redox status may have far reaching effects on the homeostasis of vasculature.
|
Platelet Activation, Cardiovascular Events, and the Role of Antioxidants |
|---|
Thrombus formation within a coronary vessel is the precipitating event in myocardial infarction and unstable angina.4 Normally, the intact endothelium prevents adhesion and activation of platelets. Adhesion of platelets to the endothelium is prevented by several mechanisms, including endothelial cell production of prostacyclin and nitric oxide (NO).5,6 The occurrence of superficial intimal injury caused by endothelial denudation and deep intimal injury caused by plaque rupture expose collagen and von Willebrand factor (vWF) to platelets. Platelets then adhere directly to collagen or indirectly via the binding of vWF to the glycoprotein (GP) Ib/IX matrix. Local platelet activation stimulates further thrombus formation and additional platelet recruitment by supporting cell-surface thrombin formation and releasing potent platelet agonists such as adenosine diphosphate (ADP), serotonin, and thromboxane A2.7 A thrombus forms as platelets aggregate via the binding of bivalent fibrinogen to GP IIb/IIIa (Figure 1).
|
Epidemiological studies initially suggested that antioxidants play a role in the prevention of cardiovascular disease. Plasma antioxidant levels were found to inversely correlate with the development of angina,8 and dietary antioxidant consumption was inversely associated with the development of clinical coronary artery disease.9 Because oxidative processes are important in the development of atherosclerosis, the use of antioxidant supplementation was proposed for the treatment and prevention of coronary disease. However, many studies of vitamin therapy have failed to show clinical benefit.1,10
Interestingly, studies have shown that despite lack of mortality benefit, supplemental antioxidants are associated with hemorrhagic stroke, suggesting platelet inhibition.11 The precise mechanism(s) accounting for changes attributable to antioxidants in coronary disease remains unknown. Animal and cell culture data suggest that antioxidants preserve NO bioactivity in the face of oxidative stress. Because oxidative stress may alter platelet function, it is also conceivable that the effects of antioxidants may be a consequence of their enhancing or promoting the antiplatelet effects of NO derived from both endothelial cells and platelets. As discussed, the assumption that this leads to a decrease in acute coronary syndromes secondary to platelet-dependent thrombosis has not been borne out by large clinical trials.
|
Reactive Oxygen Species and Platelet Function |
|---|
Changes in redox status occur during normal platelet stimulation. Platelet aggregation is associated with a burst of oxygen consumption12 and a marked rise in glutathione disulfide.13 Although dramatic changes in redox status occur during normal aggregation, conditions that provoke oxidative stress without inducing a florid aggregation response may also be prothrombotic.
Reactive oxygen species derived from both platelets and other vascular sources have been shown to alter platelet responses. Superoxide is produced by platelets,14,15 as are hydroperoxy derivatives of long-chain fatty acids (eg, 12-HpETE). Superoxide, in particular, is known to augment platelet aggregation responses.16 Low (µmol/L) concentrations of hydrogen peroxide, in the presence of plasma, inhibit platelet function.17 Although high (mmol/L) concentrations of hydrogen peroxide have been shown to stimulate platelet aggregation, the physiological relevance of levels greater than 1 mmol/L is questionable.18 Treatment of platelets with thrombin stimulates mitochondrial membrane potential depolarization and endogenous generation of hydrogen peroxide. In addition, thrombin-induced apoptosis may be mediated by endogenous generation of hydrogen peroxide in platelets.19
Platelet-dependent reactive oxygen species appear to come from several sources. Platelets activated with different agonists may produce intracellular reactive oxygen species by nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) oxidase.20 NAD(P)H oxidase is present in platelets, and the activation of platelets is known to be associated with the activation of a gp91phox-dependent enzyme.21 These studies have also shown that platelet production of reactive oxygen species enhances GP IIb/IIIa activation but not alpha or dense granule secretion.20 NAD(P)H oxidase inhibitors and superoxide scavengers also reduce platelet aggregation and thrombus formation on collagen.22 Collagen also induces NAD(P)H oxidase-dependent superoxide release in platelets, which in turn enhances availability of released ADP, resulting in increased platelet recruitment.23 Consistent with these studies, platelets from gp91phox-deficient patients produce only a small amount of reactive oxygen species.24
|
Nitric Oxide, Platelet Function, and Thrombosis |
|---|
Activation and recruitment of platelets is tightly regulated, and whereas reactive oxygen species may be prothrombotic, reactive nitrogen species have primarily been shown to inhibit platelet function. Adhesion of platelets to the endothelium is prevented by several mechanisms, including endothelial cell production of prostacyclin and NO.5 NO inhibits platelet activation25 and prevents thrombosis.26 Exogenous NO has been shown to inhibit the normal activation-dependent increase in the expression of platelet surface glycoproteins, including P-selectin and the integrin glycoprotein IIb/IIIa complex.27
Constitutive nitric oxide synthase (eNOS, cNOS, NOSIII) has been identified in both human platelets and megakaryoblastic cells.28 Platelet aggregation is enhanced by incubation with inhibitors of eNOS and inhibited by incubation with the eNOS substrate, L-arginine.29 Interestingly, studies report NO release from resting30 and aggregating platelets.31 Platelet NO release influences platelet recruitment to the growing thrombus,32 and impaired platelet-derived NO release is associated with acute coronary syndromes.33 Coronary risk factors are also reported to be associated with decreased platelet-derived NO levels.33 Impaired platelet NO responsiveness has also been shown to be an independent predictor of increased mortality and cardiovascular morbidity in patients with acute coronary syndromes.34 However, in animal models, deficiency of eNOS is not associated with spontaneous thrombosis.35 Interestingly, deficiency of eNOS is associated with enhanced fibrinolysis attributable to lack of NO-dependent inhibition of Weibel-Palade body release.36,37 These compensatory processes highlight the complexity of NO-dependent regulation of vascular homeostasis. Such compensatory mechanisms may partially explain the lack of spontaneous thrombosis, minimally elevated baseline blood pressure, and normal life span that are seen in animals deficient in a pivotal regulator of vascular patency.36
|
Superoxide and Platelet Function |
|---|
Oxidative stress is an important mediator of both abnormal platelet function and dysfunctional endothelium-dependent vasodilation in the setting of cardiovascular disease. Superoxide anion is an important source of oxidative stress, has direct effects, and limits the biological activity of NO. Excessive vascular superoxide production has been demonstrated in hypercholesterolemia as well as other disease states associated with endothelial dysfunction.38 The production or release of reactive oxygen species by the vasculature or platelets can evoke an oxidative stress that supports lipid peroxidation, induces cellular activation, and promotes vascular dysfunction. Superoxide (in the presence of transition metals) promotes lipid peroxidation leading to the generation of lipid alkoxyl and peroxyl radicals and causing lipid radical chain propagation reactions. This process can be terminated by NO through a reaction of NO with lipid peroxyl radicals.39 By reacting with superoxide or lipid peroxyl radicals, NO can form peroxynitrite and lipid peroxynitrite, respectively, with a resultant loss in NO bioactivity. Thus, NO is readily inactivated by oxidative stress, specifically superoxide.
It is possible that NO bioactivity is dependent on platelet antioxidant status. Platelets have a number of antioxidant defenses, including superoxide dismutase (SOD). Human platelets contain approximately 1 femtogram of SOD/platelet, or about one fifth of that present in leukocytes. Approximately 77% of platelet SOD is believed to be Cu/Zn SOD, whereas the remainder is Mn SOD. SOD plays a role in normal platelet function and the prevention of thrombosis.40 Studies suggest that dismutation of superoxide decreases platelet-dependent thrombus formation by potentiation of endogenous NO bioactivity.
|
Antioxidants and Platelet-Mediated Thrombosis |
|---|
Antioxidants may indirectly inhibit platelets through scavenging of reactive oxygen species, many of which alter platelet function. Despite the different subcellular locations of water- and lipid-soluble antioxidants, these antioxidant pathways in platelets are closely linked. Glutathione depletion in platelets leads to attenuated glutathione peroxidase activity, decreased levels of
-tocopherol, and increased lipid peroxidation.41 Tocopherol oxidation in platelets can be blocked by preincubation of platelets with ascorbate.42 In -tocopherol-depleted platelet lysates, the addition of either ascorbate or glutathione causes significant tocopherol regeneration.43 Evidence suggests that antioxidant status is an important determinant of platelet function. In normal individuals, selenium supplementation leads to increased plasma glutathione peroxidase activity and a prolongation of the bleeding time.44 Decreased human platelet antioxidant content is associated with enhanced platelet activation responses, and normal aging is associated with increased platelet aggregation.45 Smoking-induced platelet hyperactivity is associated with increased formation of lipid hydroperoxides and normalization of platelet aggregation with the addition of exogenous antioxidants.46
-Tocopherol has been shown to be a platelet inhibitor causing dose-dependent inhibition of platelet aggregation and 5-hydroxytryptamine release in response to ADP, epinephrine, and collagen.47 In men with previous coronary artery bypass graft surgery, vitamin E supplementation in the setting of colestipol-niacin treatment was associated with a reduction in coronary artery lesion progression.48 However, enthusiasm for the use of supplemental vitamin E decreased in light of other trials demonstrating no beneficial effect.10 The platelet inhibitory properties of vitamin E supplementation do not appear to be entirely irrelevant as supplementation is associated with increased hemorrhagic stroke.11
Antioxidant enzymatic mechanisms that metabolize these species also alter the prothrombotic effects of specific reactive oxygen species. One of these enzymes is glutathione peroxidase. Glutathione peroxidases are selenocysteine-containing enzymes that reduce hydrogen and lipid peroxides to their corresponding alcohols and use glutathione as an obligate cosubstrate. Hydroperoxides produced by the platelet (PGG2, 12-HpETE, and PLOOH) are metabolized by the selenium-dependent glutathione peroxidase enzyme that is also present in platelets. Glutathione peroxidase is tightly coupled to the hexose monophosphate shunt through reduced NAD(P)H which restores reduced glutathione concentrations and reestablishes the platelet thiol redox state via glutathione reductase. Glutathione depletion in platelets leads to attenuated glutathione peroxidase activity and increased lipid peroxidation. Antioxidants may indirectly inhibit platelets through the metabolism of reactive oxygen species, many of which alter platelet function. Glutathione peroxidase potentiates the inhibition of platelet function by NO by reducing LOOH.49 Impairment of this process can lead to a clinical thrombotic disorder as shown in thrombotic strokes in childhood.50
|
Inflammation, Platelets, and Oxidative Stress |
|---|
Inflammation is linked with the evolution of cardiovascular disease and acute coronary syndromes. CD40 ligand (CD40L) is involved in the initiation of an inflammatory response at the vessel wall by inducing the expression of adhesion molecules and the secretion of chemokines by vascular endothelial cells.51 In addition to the trimeric membrane-bound form, CD40L also exists in a soluble, 18-kDa form (sCD40L) that is released from platelets after stimulation.51,52 Platelets are the richest source of soluble CD40L (sCD40L) in circulation.53 sCD40L mediates stimulation-induced platelet release of reactive oxygen and nitrogen species through activation of Akt and p38 mitogen activated protein kinase (MAPK) signaling pathways. These data suggest that sCD40L plays an important role in regulating platelet-dependent inflammatory and thrombotic responses.54 Relative to oxidative stress in the platelet, redox-sensitive CD40-CD40L interactions specifically induce activation of Akt and p38 MAPK, leading to stimulation of nuclear factor kappaB and enhanced synthesis of CD40L and MCP1.55 Increased CD40L and MCP1 also contribute to the adherence of CD40-positive cells, such as platelets, to the vessel wall, modulating atherothrombosis.55
|
Platelets, Oxidative Stress, and Disease |
|---|
In addition to cardiovascular syndromes, other diseases have been associated with redox imbalance, reactive oxygen species production, and altered platelet function. Intracellular Ca2+ homeostasis in platelets of patients with non–insulin-dependent diabetes mellitus (NIDDM) has been reported to be altered, leading to an increased adhesiveness and spontaneous aggregation. Treatment of platelets from NIDDM patients with reactive oxygen species inhibitors can alter these processes.56 It has also been shown that hydrogen peroxide and peroxyl radicals are likely involved in the enhanced Ca2+ mobilization observed in platelets from patients with type 2 diabetes, potentially leading to platelet hyperactivity and hyperaggregability.57 In patients with hypercholesterolemia, platelet-associated NAD(P)H oxidase produces a thrombogenic phenotype and mediates the arteriolar dysfunction.20
Platelet superoxide production in patients with hypertension alone and in patients with coexistent diabetes mellitus has been examined. It was shown that eNOS can reside in the uncoupled state in patients with hypertension and, to a greater extent, in patients with coexisting hypertension and diabetes, and that this contributes significantly to increased superoxide production in these disease states.58
|
The Effect of Therapeutics on Platelet-Dependent Oxidative Stress |
|---|
Specific disease states are associated with platelet oxidative stress, and several relevant cardiovascular therapeutics have been found to alter oxidative-dependent platelet function. It has been shown that both aspirin and pravastatin inhibit lectin-like oxidized LDL receptor 1 (LOX-1) expression on platelets in part by favorably affecting reactive oxygen species and NO release from activated platelets.59 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibition also improves endothelial function, increases systemic NO bioavailability, and inhibits exaggerated platelet activation in an animal model of heart failure.60 A study of GP IIb/IIIa inhibitors also showed that modified aggregation induced membrane translocation of the platelet proteins eNOS and NAD(P)H oxidase (p67phox and p47phox), known to contribute to the generation of NO and superoxide, respectively.61
At therapeutically relevant concentrations, dipyridamole suppresses the formation of reactive oxygen species in platelets and endothelial cells and improves cellular redox status, with data suggesting that the redox-dependent properties of dipyridamole have a direct effect on vascular cells.62 In addition, dipyridamole enhances platelet inhibition by amplifying the signaling of NO donors suggesting that enhancement of endothelium-dependent NO/cGMP-mediated signaling may be a relevant component of dipyridamole effect.63
Polymeric flavonoids, such as those found in red wine and purple grapes, contain antioxidant properties believed to be protective against cardiovascular events. Extracts from grape skins or seeds alter platelet release of reactive oxygen intermediates with enhanced NO release and attenuated superoxide production. Incubation with seed or skin extracts led to an immediate attenuation of release of the inflammatory mediator, sCD40L.64 The polyphenols quercetin and catechin synergistically act in reducing platelet recruitment via inhibition of PKC-dependent NAD(P)H oxidase activation. This results in NO-mediated platelet GP IIb/IIIa downregulation.65
|
Summary |
|---|
When quiescent, platelet activation in the vasculature is limited by endothelial production of NO and prostacyclin but, in the atherosclerotic vessel, this process may be impaired. Numerous diseases including cardiovascular disease are associated with increased oxidative stress. This oxidant stress and decreased antioxidant levels found in cardiovascular disease are also associated with changes in platelet function. However, as demonstrated by the failure of antioxidant supplementation for the prevention of cardiovascular disease, the simple interpretation of redox balance/antioxidants versus oxidative stress in disease is likely simplistic. Although antioxidants, such as
-tocopherol, inhibit platelet aggregation, the interaction between reactive oxygen species, antioxidants, and NO may contribute to platelet aggregability and thrombus formation although not always with the anticipated clinical response. In summary, the regulation of oxidative stress as well as reactive oxygen and nitrogen species plays an important role in platelet function and thrombosis and the clinical expression of thrombotic events.
|
Acknowledgments |
|---|
Disclosures
Dr. Freedman received research support from Boehringer Ingelheim Pharmaceuticals.
|
Footnotes |
|---|
Original received November 9, 2007; final version accepted December 19, 2007.
|
References |
|---|
1. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 154–160.
2. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984; 310: 1137–1140.[Abstract]
3. Davies MJ. A macro and micro view of coronary vascular insult with ischemic heart disease. Circulation. 1990; 82 (suppl 3): II38–II46.[Medline] [Order article via Infotrieve]
4. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980; 303: 897–902.[Abstract]
5. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 1992; 85: 2284–2290.
6. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987; 2: 1057–1058.[Medline] [Order article via Infotrieve]
7. Santos MT, Valles J, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Eiroa AM, Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest. 1991; 87: 571–580.[Medline] [Order article via Infotrieve]
8. Riemersma RA, Wood DA, Macintyre CC, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, E, and carotene. Lancet. 1991; 337: 1–5.[CrossRef][Medline] [Order article via Infotrieve]
9. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willet WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993; 328: 1450–1456.
10. de Gaetano G, the Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001; 357: 89–95.[CrossRef][Medline] [Order article via Infotrieve]
11. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994; 330: 1029–1035.
12. Bressler NM, Broekman MJ, Marcus AJ. Concurrent studies of oxygen consumption and aggregation in stimulated human platelets. Blood. 1979; 53: 167–178.
13. Burch JW, Burch PT. Glutathione disulfide production during arachidonic acid oxygenation in human platelets. Prostaglandins. 1990; 39: 123–134.[CrossRef][Medline] [Order article via Infotrieve]
14. Freedman JE, Li L, Sauter R, Keaney JF Jr. alpha-Tocopherol and protein kinase C inhibition enhance platelet-derived nitric oxide release. FASEB J. 2000; 14: 2377–2379.
15. Marcus AJ. Pathways of oxygen utilization by stimulated platelets and leukocytes. Semin Hematol. 1979; 16: 188–195.[Medline] [Order article via Infotrieve]
16. Handin RI, Karabin R, Boxer GJ. Enhancement of platelet function by superoxide anion. J Clin Invest. 1977; 59: 959–965.[Medline] [Order article via Infotrieve]
17. Stuart MJ, Holmsen H. Hydrogen peroxide, an inhibitor of platelet function: effect on adenine nucleotide metabolism, and the release reaction. Am J Hematol. 1977; 2: 53–63.[Medline] [Order article via Infotrieve]
18. Rodvein R, Lindon JN, Levine PH. Physiology and ultrastructure of the blood platelet following exposure to hydrogen peroxide. Br J Haematol. 1976; 33: 19–26.[Medline] [Order article via Infotrieve]
19. Lopez JJ, Salido GM, Gómez-Arteta E, Rosado JA, Pariente JA. Thrombin induces apoptotic events through the generation of reactive oxygen species in human platelets. J Thromb Haemost. 2007; 5: 1283–1291.[CrossRef][Medline] [Order article via Infotrieve]
20. Stokes KY, Russell JM, Jennings MH, Alexander JS, Granger DN. Platelet-associated NAD(P)H oxidase contributes to the thrombogenic phenotype induced by hypercholesterolemia. Free Radic Biol Med. 2007; 43: 22–30.[CrossRef][Medline] [Order article via Infotrieve]
21. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation. 2004; 110: 1326–1329.
22. Begonja AJ, Gambaryan S, Geiger J, Aktas B, Pozgajova M, Nieswandt B, Walter U. Platelet NAD(P)H-oxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway. Blood. 2005; 106: 2757–2760.
23. Krötz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss V, Pohl U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood. 2002; 100: 917–924.
24. Carnevale R, Pignatelli P, Lenti L, Buchetti B, Sanguigni V, Di Santo S, Violi F. LDL are oxidatively modified by platelets via GP91(phox) and accumulate in human monocytes. FASEB J. 2007; 21: 927–934.
25. Cooke JP, Stamler J, Andon N, Davies PF, McKinley G, Loscalzo J. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol. 1990; 259: H804–H812.[Medline] [Order article via Infotrieve]
26. Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest. 1992; 90: 1718–1725.[Medline] [Order article via Infotrieve]
27. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001; 104: 1533–1537.
28. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med. 1995; 125: 370–377.[Medline] [Order article via Infotrieve]
29. Chen LY, Mehta JL. Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J Pharmacol Exp Ther. 1996; 276: 253–257.
30. Zhou Q, Hellermann GR, Solomonson LP. Nitric oxide release from resting human platelets. Thromb Res. 1995; 77: 87–96.[CrossRef][Medline] [Order article via Infotrieve]
31. Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemost. 1993; 70: 36–41.[Medline] [Order article via Infotrieve]
32. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF Jr, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997; 100: 350–356.[Medline] [Order article via Infotrieve]
33. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF Jr, Vita JA. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation. 1998; 98: 1481–1486.
34. Willoughby SR, Stewart S, Holmes AS, Chirkov YY, Horowitz JD. Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2005; 25: 2661–2666.
35. Freedman JE, Sauter R, Battinelli EM, Ault K, Knowles C, Huang PL, Loscalzo J. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res. 1999; 84: 1416–1421.
36. Iafrati MD, Vitseva O, Tanriverdi K, Blair P, Rex S, Chakrabarti S, Varghese S, Freedman JE. Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. Am J Physiol Heart Circ Physiol. 2005; 288: H1627–H1632.
37. Matsushita K, Morrell CN, Cambien B, Yang SX, Yamakuchi M, Bao C, Hara MR, Quick RA, Cao W, O’Rourke B, Lowenstein JM, Pevsner J, Wagner DD, Lowenstein CJ. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003; 115: 139–150.[CrossRef][Medline] [Order article via Infotrieve]
38. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993; 91: 2546–2551.[Medline] [Order article via Infotrieve]
39. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, Freeman BA. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem. 1994; 269: 26066–26075.
40. Meng YY, Trachtenburg J, Ryan US, Abendschein DR. Potentiation of endogenous nitric oxide with superoxide dismutase inhibits platelet-mediated thrombosis in injured and stenotic arteries. J Am Coll Cardiol. 1995; 25: 269–275.[Abstract]
41. Calzada C, Véricel E, Lagarde M. Decrease in platelet reduced glutathione increases lipoxygenase activity and decreases vitamin E. Lipids. 1991; 26: 696–699.[CrossRef][Medline] [Order article via Infotrieve]
42. Vatassery GT, Smith WE, Quach HT. Ascorbic acid, glutathione and synthetic antioxidants prevent the oxidation of vitamin E in platelets. Lipids. 1989; 24: 1043–1047.[Medline] [Order article via Infotrieve]
43. Chan AC, Tran K, Raynor T, Ganz PR, Chow CK. Regeneration of vitamin E in human platelets. J Biol Chem. 1991; 266: 17290–17295.
44. Schiavon R, Freeman GE, Guidi GC, Perona G, Zatti M, Kakkar VV. Selenium enhances prostacyclin production by cultured endothelial cells: possible explanation for increased bleeding times in volunteers taking selenium as a dietary supplement. Thromb Res. 1984; 34: 389–396.[CrossRef][Medline] [Order article via Infotrieve]
45. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature. 1975; 253: 355–357.[CrossRef][Medline] [Order article via Infotrieve]
46. Blache D. Involvement of hydrogen and lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. Am J Physiol. 1995; 268: H679–H685.[Medline] [Order article via Infotrieve]
47. Steiner M. Effect of alpha-tocopherol administration on platelet function in man. Thromb Haemost. 1983; 49: 73–77.[Medline] [Order article via Infotrieve]
48. Hodis HN, Mack WJ, LaBree L, Cashin-Hemphill L, Sevanian A, Johnson R, Azen SP. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA. 1995; 273: 1849–1854.
49. Freedman JE, Frei B, Welch GN, Loscalzo J. Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols. J Clin Invest. 1995; 96: 394–400.[Medline] [Order article via Infotrieve]
50. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996; 97: 979–987.[Medline] [Order article via Infotrieve]
51. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998; 391: 591–594.[CrossRef][Medline] [Order article via Infotrieve]
52. Jin Y, Nonoyama S, Morio T, Imai K, Ochs HD, Mizutani S. Characterization of soluble CD40 ligand released from human activated platelets. J Med Dent Sci. 2001; 48: 23–27.[Medline] [Order article via Infotrieve]
53. Krötz F, Sohn HY, Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol. 2004; 24: 1988–1996.
54. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol. 2005; 25: 2428–2434.
55. Chakrabarti S, Blair P, Freedman JE. CD40-40L signaling in vascular inflammation. J Biol Chem. 2007; 282: 18307–18317.
56. Jardín I, Redondo PC, Salido GM, Pariente JA, Rosado JA. Endogenously generated reactive oxygen species reduce PMCA activity in platelets from patients with non-insulin-dependent diabetes mellitus. Platelets. 2006; 17: 283–288.[CrossRef][Medline] [Order article via Infotrieve]
57. Redondo PC, Jardín I, Hernández-Cruz JM, Pariente JA, Salido GM, Rosado JA. Hydrogen peroxide and peroxynitrite enhance Ca2+ mobilization and aggregation in platelets from type 2 diabetic patients. Biochem Biophys Res Commun. 2005; 333: 794–802.[CrossRef][Medline] [Order article via Infotrieve]
58. Dixon LJ, Hughes SM, Rooney K, Madden A, Devine A, Leahey W, Henry W, Johnston GD, McVeigh GE. Increased superoxide production in hypertensive patients with diabetes mellitus: role of nitric oxide synthase. Am J Hypertens. 2005; 18: 839–843.[CrossRef][Medline] [Order article via Infotrieve]
59. Marwali MR, Hu C, Mohandas B, Dandapat A, Deonikar P, Chen J, Cawich I, Tatsuya T, Kavdia M, Mehta JL. Modulation of ADP-induced platelet activation by aspirin and pravastatin. J Pharmacol Exp Ther. In press.
60. Schäfer A, Fraccarollo D, Eigenthaler M, Tas P, Firnschild A, Frantz S, Ertl G, Bauersachs J. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol. 2005; 25: 1071–1077.
61. Chakrabarti S, Clutton P, Varghese S, Cox D, Mascelli MA, Freedman JE. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release. Thromb Res. 2004; 113: 225–233.[CrossRef][Medline] [Order article via Infotrieve]
62. Chakrabarti S, Vitseva O, Iyu D, Varghese S, Freedman JE. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J Pharmacol Exp Ther. 2005; 315: 494–500.
63. Aktas B, Utz A, Hoenig-Liedl P, Walter U, Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke. 2003; 34: 764–769.
64. Vitseva O, Varghese S, Chakrabarti S, Folts JD, Freedman JE. Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates. J Cardiovasc Pharmacol. 2005; 46: 445–451.[CrossRef][Medline] [Order article via Infotrieve]
65. Pignatelli P, Di Santo S, Buchetti B, Sanguigni V, Brunelli A, Violi F. Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment. FASEB J. 2006; 20: 1082–1089.
This article has been cited by other articles:
 |
|
 |
|
  A. Brill, A. K. Chauhan, M. Canault, M. T. Walsh, W. Bergmeier, and D. D. Wagner Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion Cardiovasc Res, October 1, 2009; 84(1): 137 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Morrell Reactive Oxygen Species: Finding the Right Balance Circ. Res., September 12, 2008; 103(6): 571 - 572. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||